Clene Inc. (BOATS:CLNN) Financings

Clene Inc.

Financings

RaiseDate
Registered direct offering of common stock
Closed: US$4M raised · US$3.28 a share
Buyers: David Matlin (Led the offering); Kensington Capital Holdings
Insiders: Led by the Chairman of the Board, David Matlin, alongside the Chief Executive Officer and other existing shareholders including insiders
Use of proceeds: Fund operations through mid-first quarter 2027, beyond the potential FDA decision on accepting the CNM-Au8 NDA for review
Sep 21, 2026
Registered direct offering of common stock
Announced: about US$7M · US$7 a share · Canaccord Genuity LLC
Dealers: Canaccord Genuity LLC (lead)
Use of proceeds: General corporate purposes, NDA filing for CNM-Au8, expanded access and Phase 3 trial, manufacturing expansion, commercialization and early-stage R&D
May 5, 2026
Registered direct offering of common stock with Series A and Series B warrants
Announced: about US$28M · US$6.5 a share · Warrants at US$6 · BTIG, LLC
Dealers: BTIG, LLC (lead)
Buyers: Boxer Capital; Coastlands Capital; Vivo Capital
Insiders: Offering priced above market to new, existing and insider investors, including other current insider investors
Use of proceeds: Fund operations through potential FDA NDA acceptance and approval and commercialization of CNM-Au8 in ALS
Jan 9, 2026
Not stated
Closed: US$1.2M raised
Use of proceeds: Fund operations into the second quarter of 2026
Nov 13, 2025
Equity
Closed: US$1.9M raised
Use of proceeds: To fund operations into the first quarter of 2026
Aug 14, 2025
Convertible debt facility
Made bigger: US$1.5M
Use of proceeds: To fund operations into the first quarter of 2026
Aug 14, 2025
Secured, partially convertible note
Announced: US$10M
Insiders: The note was signed with three entities, all of which are affiliated with Clene
Use of proceeds: Repay the remaining Avenue Capital senior loan and extend cash runway to generate data for the CNM-Au8 ALS drug application
Dec 19, 2024

Read by 6ix AI from the company's releases